XOMA vs. VNDA, VSTM, EBS, LXRX, RIGL, SYRS, RGLS, CUE, OPK, and INVA
Should you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Emergent BioSolutions (EBS), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Syros Pharmaceuticals (SYRS), Regulus Therapeutics (RGLS), Cue Biopharma (CUE), OPKO Health (OPK), and Innoviva (INVA). These companies are all part of the "pharmaceutical preparations" industry.
Vanda Pharmaceuticals (NASDAQ:VNDA) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.
Vanda Pharmaceuticals has higher revenue and earnings than XOMA. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than XOMA, indicating that it is currently the more affordable of the two stocks.
Vanda Pharmaceuticals has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, XOMA has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 7.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 7.2% of XOMA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Vanda Pharmaceuticals has a net margin of -2.75% compared to Vanda Pharmaceuticals' net margin of -705.23%. XOMA's return on equity of -0.90% beat Vanda Pharmaceuticals' return on equity.
Vanda Pharmaceuticals received 104 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 65.95% of users gave XOMA an outperform vote.
In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than XOMA. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 2 mentions for XOMA. Vanda Pharmaceuticals' average media sentiment score of 1.24 beat XOMA's score of 0.12 indicating that XOMA is being referred to more favorably in the news media.
XOMA has a consensus price target of $57.00, indicating a potential upside of 123.53%. Given Vanda Pharmaceuticals' higher possible upside, analysts clearly believe XOMA is more favorable than Vanda Pharmaceuticals.
Summary
Vanda Pharmaceuticals beats XOMA on 11 of the 17 factors compared between the two stocks.
Get XOMA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
